Cost-effectiveness and cost-utility of long-term management strategies for heartburn.
暂无分享,去创建一个
Andrew Briggs | Ron Goeree | Bernie J O'Brien | B. O'brien | R. Goeree | A. Briggs | G. Blackhouse | J. Marshall | Gordon Blackhouse | John Marshall | Rameeta Lad | R. Lad
[1] Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization , 2000 .
[2] B. Hazenberg,et al. Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid. , 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[3] A. Ippoliti,et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. , 1992, Gastroenterology.
[4] John Hornberger,et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease , 2000, American Journal of Gastroenterology.
[5] C. Fenger,et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial , 1988, British medical journal.
[6] J. Mills,et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. , 1989, Alimentary pharmacology & therapeutics.
[7] F. Pace,et al. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. , 1992, Journal of clinical gastroenterology.
[8] J. Galmiche,et al. Treating the symptoms of gastro‐oesophageal reflux disease: a double‐blind comparison of omeprazole and cisapride , 1997, Alimentary pharmacology & therapeutics.
[9] A. Hungin,et al. Long-term prescribing of proton pump inhibitors in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.
[10] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[11] S. Zuberi,et al. Lansoprazole--a new proton pump inhibitor. , 1995, JPMA. The Journal of the Pakistan Medical Association.
[12] I. Wiklund,et al. Gastro‐oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole , 1998 .
[13] M. Robinson,et al. Effective Maintenance Treatment of Reflux Esophagitis with Low-Dose Lansoprazole , 1996, Annals of Internal Medicine.
[14] Dekkers,et al. Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux disease , 1999 .
[15] A. Klauser,et al. Symptoms in gastro-oesophageal reflux disease , 1990, The Lancet.
[16] J. Richter,et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. , 1996, The American journal of gastroenterology.
[17] L. Lundell,et al. Omepmazole or high‐dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ‘standard doses’of H2‐receptor antagonists , 1990 .
[18] J. Selby,et al. Costs of acid-related disorders to a health maintenance organization. , 1997, The American journal of medicine.
[19] M. el-Bassoussi,et al. Cimetidine, Metoclopramide, or Placebo in the Treatment of Symptomatic Gastroesophageal Reflux , 1980, Journal of clinical gastroenterology.
[20] I. Forgacs,et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. , 1990, Gut.
[21] A. Axon,et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro‐oesophageal reflux disease‐associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis , 1997, Alimentary pharmacology & therapeutics.
[22] D. Witt,et al. Controversies Surrounding Estrogen Use in Postmenopausal Women , 1997, The Annals of pharmacotherapy.
[23] P. Maton,et al. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease—a prospective, controlled trial , 1999, Alimentary pharmacology & therapeutics.
[24] I. Moules,et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis , 1995, Alimentary pharmacology & therapeutics.
[25] J. Richter,et al. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. , 1997, The American journal of gastroenterology.
[26] G. Tytgat. Clinical efficacy of sucralfate in reflux esophagitis. Comparison with cimetidine. , 1987, The American journal of medicine.
[27] R. Hunt,et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. , 1997, Gastroenterology.
[28] M. Gerretsen,et al. Lansoprazole 30mg versus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial) , 1996 .
[29] A. Hungin,et al. Gastro-oesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings , 1995 .
[30] R. Corinaldesi,et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study , 1995, Alimentary pharmacology & therapeutics.
[31] G. Tytgat,et al. Oral cimetidine in reflux esophagitis: a double blind controlled trial. , 1978, Gastroenterology.
[32] T. Humphries,et al. Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis , 1991, Alimentary pharmacology & therapeutics.
[33] J. Dent,et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. , 1988, Gastroenterology.
[34] A. Berstad,et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks , 1999, BMJ.
[35] L. Kuller,et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.
[36] B. Cooper,et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis , 1996, Alimentary pharmacology & therapeutics.
[37] T. Humphries,et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. , 1991, Archives of internal medicine.
[38] S. Laws,et al. Effect of three ranitidine dosage regimens in the treatment of reflux oesophagitis : results of a multicentre trial , 1991 .
[39] P. Kahrilas,et al. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial , 1999, American Journal of Gastroenterology.
[40] D. Graham,et al. Why do apparently healthy people use antacid tablets? , 1983, The American journal of gastroenterology.
[41] A. McCullough,et al. Omeprazole is superior to ranitidine plus metoclopramide in the short‐term treatment of erosive oesophagitis , 1993, Alimentary pharmacology & therapeutics.
[42] H. Raiffa,et al. Introduction to Statistical Decision Theory , 1996 .
[43] G. Tougas,et al. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study , 1999, American Journal of Gastroenterology.
[44] D. Drossman,et al. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. , 1999, Journal of clinical gastroenterology.
[45] A. Barkun,et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[46] P. Leese. Comparison of the effects , 1992 .
[47] W. Londong,et al. The effect of combined therapy with ranitidine and pirenzepine in the treatment of reflux oesophagitis , 1992, Alimentary pharmacology & therapeutics.
[48] I. Trotman,et al. Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease. , 1986, Hepato-gastroenterology.
[49] M. Dakkak,et al. COMPARING THE EFFICACY OF CISAPRIDE AND RANITIDINE IN OESOPHAGITIS: A DOUBLE‐BLIND, PARALLEL GROUP STUDY IN GENERAL PRACTICE , 1994, The British journal of clinical practice.
[50] John C. Hershey,et al. Carrier Screening for Cystic Fibrosis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[51] C. Bate,et al. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? , 1993, Alimentary pharmacology & therapeutics.
[52] B. Simon,et al. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. , 1987, The American journal of medicine.
[53] D. Colin-Jones,et al. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. , 1990, Gut.
[54] J. Jansen,et al. DOUBLE-BLIND MULTICENTRE COMPARISON OF OMEPRAZOLE AND RANITIDINE IN THE TREATMENT OF REFLUX OESOPHAGITIS , 1987, The Lancet.
[55] G. Porro,et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine , 1999, BMJ.
[56] A Gafni,et al. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[57] C. Fenger,et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. , 1995, Scandinavian journal of gastroenterology.
[58] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[59] T. Humphries,et al. Famotidine Relieves Symptoms of Gastroesophageal Reflux Disease and Heals Erosions and Ulcerations: Results of a Multicenter, Placebo-Controlled, Dose-Ranging Study , 1991 .
[60] A. Axon,et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis , 1996, Alimentary pharmacology & therapeutics.
[61] M. Classen,et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. , 1995, Journal of clinical gastroenterology.
[62] C. Bate,et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. , 1995, Gut.
[63] J. Fleiss. Review papers : The statistical basis of meta-analysis , 1993 .
[64] J. Mössner,et al. A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis : a multicentre trial , 1995, Alimentary pharmacology & therapeutics.
[65] B. Edwin,et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. , 1994, Gastroenterology.